Quarterly Journal 50-3
In This Section
Reza Roghani Esfahani and Howard Bromberg
Despite being expressly protected by the U.S. Constitution, patent protection and enforcement for marijuana-related inventions is mired in many questions. These questions are a subset of the contradictions in the law of marijuana, where the federal government prohibits marijuana use and yet many of the states legalize, regulate, and tax it. In patent procurement context, these questions arise because of the interplay between marijuana prohibition as a Schedule I drug and the patentability requirements of the Patent Act. In patent enforcement context, these questions are the result of the federal judiciary’s responsibility to interpret and administer all federal laws—including the Controlled Substance Act, classifying marijuana as a Schedule I drug, and the Patent Act, demanding remedy for infringement of patents that necessarily advance illegal activity. This article examines the interface of some of the patentability requirements of the Patent Act with marijuana-related inventions. The article concludes that although marijuana-related inventions are likely patentable, criminalization of marijuana affects the quality of the granted patents. Further, this article identifies several issues that arise in enforcing a marijuana-related patent in federal court. These issues may include securing representation, dangers of self-incrimination, and identifying infringing parties. As a byproduct of these issues, this article concludes that the marijuana industry may be particularly vulnerable to frivolous lawsuits by Patent Assertion Entities.
Henry Loznev
Jordan M. Cowger
NOT SO NATURAL PHENOMENA: A LOOK AT § 101’S IMPACT ON BIOTECH PATENTS
This note seeks to address the uncertainty surrounding patent eligibility for DNA and DNA-derivative pharmaceuticals. Inconsistent judicial decisions and lack of action by the Supreme Court make this issue ripe for resolution. Due to the importance of DNA-derivative pharmaceuticals—not just to precision medicine but also to the United States’ position as a life science leader in the global economy—Congress must take action now. Following Europe’s approach, Congress should adopt a revised version of the draft Tillis-Coons STRONGER Patents Act, which includes an additional subsection to section 101 specifically calling for patent protection for DNA-derivative inventions.
Joshua A. Lopez
TECHNOLOGICAL FAULT LINES: THE PROBLEMS WITH TAILORING PATENT ELIGIBILITY AT THE USPTO
Many members of the patent community seek clarification of subject matter eligibility law, but administrative rulemaking would be a problematic approach. The Supreme Court has carved out what qualifies as a “process, machine, manufacture, or composition of matter” under 35 U.S.C. § 101 - Inventions patentable. Although the Court has dealt with this statute in decades past, it began in 2012 to reinvigorate the rule that “laws of nature, natural phenomena, and abstract ideas” are not patent eligible. Mayo, Myriad, and Alice mark the Court’s recent encounters with section 101. Respectively, these cases have heightened the patent standard for three major areas: diagnostic tools, genetics, and software. If Congress grants the USPTO rulemaking authority to clarify or enhance the eligibility standards, the agency’s rules would likely reflect a similar technological split. This is problematic because technological discrimination is prohibited under TRIPS Article 27, and divided USPTO rule makers could invite harmful divide-and-conquer influence. Legislators should work to make section 101 more fair and sensible, but they should delegate rulemaking authority with caution.
Upcoming Events
-
AIPLA 2024 Annual Meeting
October 24 to 26, 2024
Join us as we bring IP professionals together to learn and connect. More information coming soon! The 2024 Annual meeting will take place at the Gaylord National Harbor Resort. Leadership Meetings on Wednesday, October 23. Programming scheduled October 24-26. -
2024 Annual Meeting
October 24 to 26, 2024
Join us as we bring IP professionals together to learn and connect. More information coming soon! The 2024 Annual meeting will take place at the Gaylord National Harbor Resort. Leadership Meetings on Wednesday, October 23. Programming scheduled October 24-26. -
AIPLA Committee Webinar: Intellectual Property, Technology and International Dispute Resolution
November 13, 2024 8:00 PM to 9:30 PM | No CLE
AIPLA Member Exclusive Webinar! This webinar will explore the importance of considering different dispute resolution options in resolving high stakes intellectual property and technology disputes, which is often overlooked. In particular, the speakers will discuss the benefits of choosing Singapore (whether arbitration, mediation or litigation) to resolve your IP and Tech disputes. The Singapore International Arbitration Centre (SIAC) has been ranked as the most preferred arbitral institution in Asia Pacific and 2nd among the world’s top five arbitral institutions. The webinar will delve into IP dispute resolution in SIAC, as well as via the Singapore International Mediation Centre (SIMC), and the Singapore International Commercial Court (SICC). -
AIPLA CLE Webinar: IP in Space
November 20, 2024 12:30 PM to 2:00 PM | Up to 90 Mins CLE Pending
Coming Soon! -
2025 Leadership Forum
January 29 to 30, 2025
AIPLA Leadership Forum – Elevate Yourself, Inspire the Future. This invitation-only two-day program will address building strong leadership skills for all levels of experience. More details coming soon.